Comparison of an interactive voice response system and smartphone application in the identification of gout flares

Nada Elmagboul, Brian W Coburn, Jeffrey Foster, Amy Mudano, Joshua Melnick, Debra Bergman, Shuo Yang, David Redden, Lang Chen, Cooper Filby, Jeffrey R Curtis, Ted R Mikuls, Kenneth G Saag, Nada Elmagboul, Brian W Coburn, Jeffrey Foster, Amy Mudano, Joshua Melnick, Debra Bergman, Shuo Yang, David Redden, Lang Chen, Cooper Filby, Jeffrey R Curtis, Ted R Mikuls, Kenneth G Saag

Abstract

Objective: To examine the feasibility, preference, and satisfaction of an interactive voice response (IVR) system versus a customized smartphone application (StudyBuddy) to capture gout flares METHODS: In this 24-week prospective, randomized, crossover, open-label pilot study, 44 gout patients were randomized to IVR vs. StudyBuddy and were crossed over to the other technology after 12 weeks. Flares were reported via weekly (and later daily) scheduled StudyBuddy or IVR queries. Feasibility was ascertained via response rate to scheduled queries. At 12 and 24 weeks, participants completed preference/satisfaction surveys. Preference and satisfaction were assessed using dichotomous or ordinal questions. Sensitivity was assessed by the frequency of flare reporting with each approach.

Results: Thirty-eight of 44 participants completed the study. Among completers, feasibility was similar for IVR (81%) and StudyBuddy (80%). Conversely, most (74%) preferred StudyBuddy. Measures of satisfaction (ease of use, preference over in-person clinic visits, and willingness for future use) were similar between the IVR and StudyBuddy; however, more participants deemed the StudyBuddy as convenient (95% vs. 73%, P = 0.01) and less disruptive (97% vs. 82%, P = 0.03). Although the per patient number of weeks in flare was not significantly different (mean 3.4 vs. 2.6 weeks/patient, P = 0.15), the StudyBuddy captured more of the total flare weeks (35%) than IVR (27%, P = 0.02).

Conclusion: A smartphone application and IVR demonstrated similar feasibility but overall sensitivity to capture gout flares and participant preference were greater for the smartphone application. Participant preference for the smartphone application appeared to relate to perceptions of greater convenience and lower disruption.

Trial registration: NCT, NCT02855437 . Registered 4 August 2016.

Keywords: Gout flares; Interactive voice response system; Smartphone application.

Conflict of interest statement

T. Mikuls had a research support from Ironwood/Astra Zeneca and Horizon. K. Saag had a research support from Ironwood, Horizon, Takeda, and Sobi and is a consultant at Horizon, Sobi, Shanton, and Takeda. The other authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Screenshots of the StudyBuddy (GoutPRO) application

References

    1. Schumacher H. RALPH, Becker Michael A., Wortmann Robert L., MacDonald Patricia A., Hunt Barbara, Streit Janet, Lademacher Christopher, Joseph-Ridge Nancy. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis & Rheumatism. 2008;59(11):1540–1548. doi: 10.1002/art.24209.
    1. So Alexander, De Meulemeester Marc, Pikhlak Andrey, Yücel A. Eftal, Richard Dominik, Murphy Valda, Arulmani Udayasankar, Sallstig Peter, Schlesinger Naomi. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis & Rheumatism. 2010;62(10):3064–3076. doi: 10.1002/art.27600.
    1. Timilsina S., Brittan K., O'Dell J.R., Brophy M., Davis-Karim A., Henrie A.M., Neogi T., Newcomb J., Palevsky P.M., Pillinger M.H., Pittman D., Taylor T.H., Wu H., Mikuls T.R. Design and Rationale for the Veterans Affairs “Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat” Trial. Contemporary Clinical Trials. 2018;68:102–108. doi: 10.1016/j.cct.2018.03.015.
    1. Schumacher H. Ralph, Sundy John S., Terkeltaub Robert, Knapp Howard R., Mellis Scott J., Stahl Neil, Yancopoulos George D., Soo Yuhwen, King-Davis Shirletta, Weinstein Steven P., Radin Allen R. Rilonacept (Interleukin-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism. 2012;64(3):876–884. doi: 10.1002/art.33412.
    1. Saag K., Fitz-Patrick D., Kopicko J., Fung M., Bhakta N., Adler S., Storgard C., Baumgartner S., Becker M. FRI0320 Lesinurad, A Selective URIC Acid Reabsorption Inhibitor, in Combination with Allopurinol: Results from a Phase III Study in Gout Patients Having an Inadequate Response to Standard of Care (Clear 1) Annals of the Rheumatic Diseases. 2015;74(Suppl 2):540.1-540.
    1. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63. doi: 10.1186/ar2978.
    1. Becker MA, Schumacher HR, Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–2461. doi: 10.1056/NEJMoa050373.
    1. Dalbeth Nicola, Bardin Thomas, Doherty Michael, Lioté Frédéric, Richette Pascal, Saag Kenneth G., So Alexander K., Stamp Lisa K., Choi Hyon K., Terkeltaub Robert. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) Nature Reviews Rheumatology. 2017;13(9):561–568. doi: 10.1038/nrrheum.2017.126.
    1. Qaseem A, Harris RP, Forciea MA. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166:58–68. doi: 10.7326/M16-0570.
    1. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64:1431–1446. doi: 10.1002/acr.21772.
    1. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen T L, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche A K, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases. 2016;76(1):29–42. doi: 10.1136/annrheumdis-2016-209707.
    1. Schlesinger N., Mysler E., Lin H.-Y., De Meulemeester M., Rovensky J., Arulmani U., Balfour A., Krammer G., Sallstig P., So A. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Annals of the Rheumatic Diseases. 2011;70(7):1264–1271. doi: 10.1136/ard.2010.144063.
    1. Nguyen Amy D., Baysari Melissa T., Kannangara Diluk R.W., Tariq Amina, Lau Annie Y.S., Westbrook Johanna I., Day Richard O. Mobile applications to enhance self-management of gout. International Journal of Medical Informatics. 2016;94:67–74. doi: 10.1016/j.ijmedinf.2016.06.021.
    1. Boulos MN, Wheeler S, Tavares C, Jones R. How smartphones are changing the face of mobile and participatory healthcare: an overview, with example from eCAALYX. Biomed Eng Online. 2011;10:24. doi: 10.1186/1475-925X-10-24.
    1. Lunde Pernille, Nilsson Birgitta Blakstad, Bergland Astrid, Kværner Kari Jorunn, Bye Asta. The Effectiveness of Smartphone Apps for Lifestyle Improvement in Noncommunicable Diseases: Systematic Review and Meta-Analyses. Journal of Medical Internet Research. 2018;20(5):e162. doi: 10.2196/jmir.9751.
    1. Jibb LA, Stevens BJ, Nathan PC, Seto E, Cafazzo JA, Johnston DL, et al. Implementation and preliminary effectiveness of a real-time pain management smartphone app for adolescents with cancer: a multicenter pilot clinical study. Pediatr Blood Cancer. 2017;64:e26554. doi: 10.1002/pbc.26554.
    1. W. Benjamin Nowell, Michelle Thai,Carole Wiedmeyer, Kelly Gavigan, Shilpa Venkatachalam, Seth Ginsberg, Jeffery Curtis. Digital interventions to build a patient registry for rheumatology research. Rheum Dis Clin North Am. 2019;45:173–86.
    1. Bennett AV, Keenoy K, Shouery M, Basch E, Temple LK. Evaluation of mode equivalence of the MSKCC bowel function instrument, LASA quality of life, and subjective significance questionnaire items administered by web, interactive voice response system (IVRS), and paper. Qual Life Res. 2016;25:1123–1130. doi: 10.1007/s11136-015-1162-9.
    1. Lee H, Friedman ME, Cukor P, Ahern D. Interactive voice response system (IVRS) in health care services. Nurs Outlook. 2003;51:277–283. doi: 10.1016/S0029-6554(03)00161-1.
    1. Daftary A, Hirsch-Moverman Y, Kassie GM, Melaku Z, Gadisa T, Saito S, et al. A qualitative evaluation of the acceptability of an interactive voice response system to enhance adherence to isoniazid preventive therapy among people living with HIV in Ethiopia. AIDS Behav. 2017;21:3057–3067. doi: 10.1007/s10461-016-1432-8.
    1. Gaffo AL, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, et al. Brief report: validation of a definition of flare in patients with established gout. Arthritis Rheumatol. 2018;70:462–467. doi: 10.1002/art.40381.
    1. Yen PY, Wantland D, Bakken S. Development of a customizable health IT usability evaluation scale. AMIA Annu Symp Proc. 2010;2010:917–921.
    1. Senn SS. Cross-over trials in clinical research, West Sussex: John Wiley & Sons Ltd; 2002.
    1. Jonassaint CR, Shah N, Jonassaint J, De Castro L. Usability and feasibility of an mHealth intervention for monitoring and managing pain symptoms in sickle cell disease: the Sickle Cell Disease Mobile application to Record Symptoms via Technology (SMART) Hemoglobin. 2015;39:162–168. doi: 10.3109/03630269.2015.1025141.
    1. Ambrosini GL, Hurworth M, Giglia R, Trapp G, Strauss P. Feasibility of a commercial smartphone application for dietary assessment in epidemiological research and comparison with 24-h dietary recalls. Nutr J. 2018;17:5. doi: 10.1186/s12937-018-0315-4.
    1. Schroder KE, Johnson CJ. Interactive voice response technology to measure HIV-related behavior. Curr HIV/AIDS Rep. 2009;6:210–216. doi: 10.1007/s11904-009-0028-6.
    1. Isetta V, Torres M, González K, Ruiz C, Dalmases M, Embid C, et al. A new mHealth application to support treatment of sleep apnoea patients. J Telemed Telecare. 2017;23:14–18. doi: 10.1177/1357633X15621848.
    1. Nishiguchi S, Ito H, Yamada M, Yoshitomi H, Furu M, Ito M, et al. Self-assessment of rheumatoid arthritis disease activity using a smartphone application. Methods Inf Med. 2016;55:65–69. doi: 10.3414/ME14-01-0106.
    1. Anguera JA, Jordan JT, Castaneda D, Gazzaley A, Areán PA. Conducting a fully mobile and randomised clinical trial for depression: access, engagement and expense. BMJ Innov. 2016;2:14–21. doi: 10.1136/bmjinnov-2015-000098.
    1. Crouthamel Michelle, Quattrocchi Emilia, Watts Sarah, Wang Sherry, Berry Pamela, Garcia-Gancedo Luis, Hamy Valentin, Williams Rachel E. Using a ResearchKit Smartphone App to Collect Rheumatoid Arthritis Symptoms From Real-World Participants: Feasibility Study. JMIR mHealth and uHealth. 2018;6(9):e177. doi: 10.2196/mhealth.9656.
    1. Heapy Alicia, Sellinger John, Higgins Diana, Chatkoff David, Bennett Tracy C., Kerns Robert D. Using Interactive Voice Response to Measure Pain and Quality of Life. Pain Medicine. 2007;8(suppl 3):S145–S154. doi: 10.1111/j.1526-4637.2007.00378.x.
    1. Skolarus TA, Holmes-Rovner M, Hawley ST, Dunn RL, Barr KL, Willard NR, et al. Monitoring quality of life among prostate cancer survivors: the feasibility of automated telephone assessment. Urology. 2012;80:1021–1026. doi: 10.1016/j.urology.2012.07.038.
    1. Kassavou A, Sutton S. Reasons for non-adherence to cardiometabolic medications, and acceptability of an interactive voice response intervention in patients with hypertension and type 2 diabetes in primary care: a qualitative study. BMJ Open. 2017;7:e015597. doi: 10.1136/bmjopen-2016-015597.
    1. Heisler M, Halasyamani L, Resnicow K, Neaton M, Shanahan J, Brown S, et al. “I am not alone”: the feasibility and acceptability of interactive voice response-facilitated telephone peer support among older adults with heart failure. Congest Heart Fail. 2007;13:149–157. doi: 10.1111/j.1527-5299.2007.06412.x.
    1. Oake N, van Walraven C, Rodger MA, Forster AJ. Effect of an interactive voice response system on oral anticoagulant management. CMAJ. 2009;180:927–933. doi: 10.1503/cmaj.081659.
    1. Hahn DL, Plane MB. Feasibility of a practical clinical trial for asthma conducted in primary care. J Am Board Family Pract. 2004;17:190–195. doi: 10.3122/jabfm.17.3.190.
    1. Lalloo C, Jibb LA, Rivera J, Agarwal A, Stinson JN. “There’s a pain app for that”: review of patient-targeted smartphone applications for pain management. Clin J Pain. 2015;31:557–563. doi: 10.1097/AJP.0000000000000171.
    1. Cai Ran A, Beste Dominik, Chaplin Hema, Varakliotis Socrates, Suffield Linda, Josephs Francesca, Sen Debajit, Wedderburn Lucy R, Ioannou Yiannakis, Hailes Stephen, Eleftheriou Despina. Developing and Evaluating JIApp: Acceptability and Usability of a Smartphone App System to Improve Self-Management in Young People With Juvenile Idiopathic Arthritis. JMIR mHealth and uHealth. 2017;5(8):e121. doi: 10.2196/mhealth.7229.
    1. Dorsey E. Ray, “Yvonne Chan Yu-Feng, McConnell Michael V., Shaw Stanley Y., Trister Andrew D., Friend Stephen H. The Use of Smartphones for Health Research. Academic Medicine. 2017;92(2):157–160. doi: 10.1097/ACM.0000000000001205.
    1. Abu-Hasaballah K, James A, Aseltine RH., Jr Lessons and pitfalls of interactive voice response in medical research. Contemp Clin Trials. 2007;28:593–602. doi: 10.1016/j.cct.2007.02.007.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi